Milada Šírová

Dr. Milada Šírová


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2006 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MŠMilada Šírová
Milada Šírová
JSJiri Strohalm
Jiri Strohalm
VŠV. Šubr
V. Šubr
DPDaniela Plocova
Daniela Plocova
PRPavel Rossmann
Pavel Rossmann
BRBlanka Rihova
Blanka Rihova

6 November 2009 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
MŠMilada Šírová
Milada Šírová
TMTomas Mrkvan
Tomas Mrkvan
TETomas Etrych
Tomas Etrych
PCPetr Chytil
Petr Chytil
PRPavel Rossmann
Pavel Rossmann
BRBlanka Rihova
Blanka Rihova

12 July 2013 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MŠMilada Šírová
Milada Šírová
SVSandra Van Vlierberghe
Sandra Van Vlierberghe
VMVeronika Matyasova
Veronika Matyasova
PRPavel Rossmann
Pavel Rossmann
ESEtienne Schacht
Etienne Schacht
BRBlanka Rihova
Blanka Rihova

1 February 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
BTBarbora Tomalova
Barbora Tomalova
MŠMilada Šírová
Milada Šírová
PRPavel Rossmann
Pavel Rossmann
RPRobert Pola
Robert Pola
JSJiri Strohalm
Jiri Strohalm
MKMarek Kovář
Marek Kovář

1 January 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
MŠMilada Šírová
Milada Šírová
JSJiří Strohalm
Jiří Strohalm
PCPetr Chytil
Petr Chytil
OLOndřej Lidický
Ondřej Lidický
JTJakub Tomala
Jakub Tomala
TETomáš Etrych
Tomáš Etrych

1 November 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MŠMilada Šírová
Milada Šírová
MKM. Kabesova
M. Kabesova
LKL. Kovar
L. Kovar
TET. Etrych
T. Etrych
JSJ. Strohalm
J. Strohalm
BRB. Rihova
B. Rihova
Treatment of murine EL4 T cell lymphoma with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates of doxorubicin (Dox) leads to complete tumor regression and to the development of therapy-dependent longlasting cancer resistance. This phenomenon occurs with two types of Dox conjugates tested, despite differences in the covalent linkage of Dox to the polymer carrier. Such a cancer resistance cannot fully express in conventional treatment with free Dox, due to substantial immunotoxicity of the treatment, which was not observed in the polymer conjugates. In this study, calreticulin (CRT) translocation and high mobility group box-1 protein (HMGB1) release was observed in EL4 cells treated with a conjugate releasing Dox by a pH-dependent manner. As a result, the treated tumor cells were engulfed by dendritic cells (DC) in vitro, and induced their expression of CD80, CD86, and MHC II maturation markers. Conjugates with Dox bound via an amide bond only increased translocation of HSPs to the membrane, which led to an elevated phagocytosis but was not sufficient to induce increase of the maturation markers on DCs in vitro. Both types of conjugates induced engulfment of the target tumor cells in vivo, that was more intense than that seen with free Dox. It means that the induction of anti-tumor immunity documented upon treatment of EL4 lymphoma with HPMA-bound Dox conjugates does not rely solely on CRT-mediated cell death, but involves multiple mechanisms.